The combination of netupitant and palonosetron was approved by the Food and Drug Administration in October 2014 for the prevention of acute and delayed chemotherapy-induced nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic chemotherapy. Netupitant and palonosetron is available as a single capsule to be administered prior to each cycle of chemotherapy. The approval was based on phase II and III data in patients undergoing treatment with moderately and highly emetogenic chemotherapy. Netupitant and palonosetron’s benefits include a convenient dosage form, dual-targeted mechanism, and favorable side effect profile, while its main limitations are cost and potential logistical issues surrounding administration. More studies are needed to adequately determine its role in therapy as well as which patients will derive the most benefit from its use.
GrundbergSMSlusherBRugoHS. Emerging treatments in chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol2013; 11: 1–18.
2.
GrundbergSMDeusonRRMavrosP. Incidence of chemotherapy-induced nausea and vomiting after modern antiemetics. Cancer2004; 100: 2261–2268.
3.
Bloechl-DaumBDeusonRRMavrosP. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol2006; 24: 4472–4478.
4.
CohenLde MoorCAEisenbergP. Chemotherapy-induced nausea and vomiting – incidence and impact on patient quality of life at community oncology settings. Support Care Cancer2007; 15: 497–503.
5.
Fernández-OrtegaPCalotoMTChirvechesE. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life. Support Care Cancer2012; 20: 3141–3148.
6.
HilariusDLKloegPHvan der WallE. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer2012; 20: 107–117.
7.
BroderMSFariaCPowersA. The impact of 5-HT3RA use on cost and utilization in patients with chemotherapy-induced nausea and vomiting: systematic review of the literature. Am Health Drug Benefits2014; 7: 171–182.
8.
HerrstedtJ. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol2008; 5: 32–43.
9.
JanelsinsMCTejaniMKamenC. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother2013; 14: 757–766.
BaschEPrestrudAAHeskethPJ. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol2011; 29: 4189–4198.
12.
RoilaFHerrstedtJAaproM. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol2010; 21: 232–243.
Eisai Inc. Akynzeo (package insert), Woodcliff Lake, NJ: Eisai Inc, 2014.
15.
GrallaRBosnjakSHonstaA. A phase 3 study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) over repeated cycles of chemotherapy. Ann Oncol2014; 25: 1333–1339.
16.
RojasCThomasAGAltJ. Palonosteron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol2010; 626: 193–199.
17.
RojasCLiYZhangJ. The antiemetic 5-HT3 receptor antagonist palonosteron inhibits substance P mediated responses in vitro and in vivo. J Pharmacol Exp Ther2010; 335: 362–368.
18.
HeskethPRossiGRizziG. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol2014; 25: 1340–1346.
19.
AaproMRugoHRossiG. A randomized phase 3 study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol2014; 25: 1328–1333.
20.
Eisai Inc. Aloxi (package insert), Woodcliff Lake, NJ: Eisai Inc, 2014.
21.
SpinelliTCalcagnileSGiulianoC. Netupitant PET imaging and ADME studies in humans. J Clin Pharmacol2014; 1: 97–108.
22.
NavariRMKoellerJM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother2003; 37: 1276–1286.
23.
In brief: intravenous ondanstron (Zofran) 32 mg withdrawn. Med Lett Drugs Ther 2012; 54: 104.
24.
GonulluGDemircanSDemiragMK. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer2012; 20: 1435–1439.
25.
SpinelliTMoresinoCBaumannS. Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial. SpringerPlus2014; 3: 389–389.
26.
Sanofi-aventis. Anzemet (package insert), New Jersey: sanofi-aventis U.S. LLC, 2014.
27.
ProStrakan. Sancuso (package insert), New Jersey: ProStrakan, 2014.
28.
GlaxoSmithKline. Zofran (package insert), North Carolina: GlaxoSmithKline, 2014.
29.
AaproMSWalkoCM. Aprepitant: drug-drug interactions in perspective. Ann Oncol2010; 21: 2316–2323.
30.
CalcagnileSLanzarottiCRossiG. Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Support Care Cancer2013; 21: 2783–2791.
31.
Merck. Emend (package insert), New Jersey: Merck, 2014.
BurkeTAWisniewskiTErnstFR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer2011; 19: 131–140.
34.
LundbergJDCrawfordBSPhillipsG. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. Support Care Cancer2014; 22: 1461–1466.
